Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
338 Leser
Artikel bewerten:
(1)

BIAL Foundation: BIAL Award in Biomedicine worth 300,000 Euros

The BIAL Foundation awards international biomedical research.

TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June. With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.

The winner will be chosen by an independent and international Jury chaired by Ralph Adolphs, Professor of Psychology, Neuroscience and Biology at Caltech (California Institute of Technology). In addition to the president, the Panel includes 12 members appointed by the European Research Council, the Council of Rectors of Portuguese Universities, the European Medical Association, the Scientific Board of the BIAL Foundation, previous winners of the BIAL Award, and editors of the British Medical Journal and the New England Journal of Medicine.

Candidates for this international award may be nominated by members of the Jury, members of the Scientific Board of the BIAL Foundation, previous BIAL Award winners, Scientific Societies, Boards or Deans of Medical Faculties, Heads of leading research institutes, and Boards or Heads of prestigious Academies. Highly qualified researchers may also nominate works, though self-nominations will not be accepted.

Ralph Adolphs, president of the Jury, expressed his high expectations for this new edition: "Given the broad nature of this award, we expect to receive nominations from organized groups of scientists with a wide range of affiliations, including in academia, scientific societies, and research institutes. We hope to receive works of high quality and relevance from scientists from any country around the world and at any stage of their career."

For Luís Portela, chairman of the BIAL Foundation, "this award aims to mobilise the scientific community to share, through nominations, relevant work by researchers from all over the world, with a view to recognising the most important scientific discoveries in the biomedical field."

In the last edition in 2021, this award distinguished an article published in Nature journal in 2017 focused on the mRNA technology used in Pfizer-BioNTech and Moderna's Covid-19 vaccines. The winning team was led by the American scientist Drew Weissman and included, at the time of the article's publication, 36 co-authors from the Universities of Pennsylvania, Duke and Kansas State (USA), Harvard Medical School (USA), National Institutes of Health (USA), Bioqual Inc. (USA), Acuitas Therapeutics (Canada), and BioNTech RNA Pharmaceuticals (Germany).

The BIAL Award in Biomedicine takes place biannually, in odd-numbered years, alternating with the Prémio BIAL de Medicina Clínica. It has the patronage of the President of the Portuguese Republic, the Council of Rectors of Portuguese Universities and the European Medical Association.

The Regulation and Nomination Form for the BIAL Award in Biomedicine 2023 are available here.

About the BIAL Foundation

The BIAL Foundation was created in 1994 by BIAL pharmaceutical company together with the Council of Rectors of Portuguese Universities with the mission of fostering the scientific study of the human being from both the physical and spiritual perspectives. It is managed by representatives from both institutions. Its activities include the awarding of scientific awards within the scope of research in Health Sciences, namely the Prémio BIAL de Medicina Clínica, the BIAL Award in Biomedicine, one of the biggest European awards in the health area, and the Maria de Sousa Award, in partnership with the Portuguese Medical Association. The BIAL Foundation also supports a Grants programme for scientific research focused on the neurophysiological and mental study of the human being in the areas of Psychophysiology and Parapsychology. Every two years since 1996, the Foundation has organised the "Behind and Beyond the Brain" Symposia, bringing together the most world-renowned experts in Neuroscience and Parapsychology, as well as the supported researchers. A non-profit institution of public utility, the BIAL Foundation has the patronage of His Excellency the President of the Portuguese Republic, the Council of Rectors of Portuguese Universities, and the Portuguese Medical Association.

Cision View original content:https://www.prnewswire.co.uk/news-releases/bial-award-in-biomedicine-worth-300-000-euros-301807532.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.